Department of Medicine

Department of Medicine

  Division of Hematology/Oncology

[Return To Index page]
photo Julien J. Fourcade, PharmD, PhD

Research Assistant Professor


Phone: 412-623-3244

Office: 1.3 Hillman Cancer Center
5117 Centre Ave
Pittsburgh, PA 15213
Phone: 412-623-3244
Administrative Assistant:
Gina Toy-Cuttler
Address: 5117 Centre Avenue
UPMC Hillman Cancer Center Suite 1.16
Pittsburgh, PA 15213
Phone: 412-623-3241
Fax: 412-623-3355
Education and Training
PharmD, University Paul Sabatier, Toulouse, France, 2003
Ph.D. in Oncology/Immunology, University of Aix-Marseille, France, 2012
Postdoctoral Associate, University of Pittsburgh, 2006
Research Interest
Dr Fourcade's research activities are focused on the study of spontaneous and vaccine-induced T cell immune responses against melanoma and other solid tumors in cancer patients, and their interaction with cancer cells and other immune cell subsets involved in anti-tumor immunity in the tumor microenvironment. In particular, Dr Fourcade is involved in the study of the multiple mechanisms leading to tumor-induced immunosuppression and tumor escape in cancer patients, including the study of multiple co-inhibitory receptors (ex: PD-1, BTLA, Tim-3, TIGIT) expressed by tumor antigen (TA)-specific effector CD8+ and CD4+ T cells and regulatory T cells present in the periphery and at tumor sites of patients with advanced cancer. In relation to this, Dr Fourcade’s aim is to assess the potential of newly designed immunotherapeutic agents targeting immune checkpoint receptors on T cells in order to reverse tumor-induced TA-specific T cell dysfunction/exhaustion and/or reverse Treg-induced immunosuppression in the context of cancer.
Clinical Interest
Dr. Fourcade's research also includes the identification of novel immunogenic antigens expressed by tumors and the clinical and immunological evaluation of new adjuvants that may help to optimize vaccines in cancer patients.
For my complete bibliography, Click Here.
Selected Publications:
Chauvin JM, Pagliano O, Fourcade J,, Sun Z, Wang H, Sander C,, Kirkwood JM, Chen TH, Maurer M, Korman AJ, Zarour HM. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest. 2015; 2015 May 1;125(5): 2046-58.
Fourcade J, Sun Z, Pagliano O, Chauvin JM, Wang H, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S,Guillaume P, Luescher IF, Krieg A, Anderson AC, Kuchroo VK, Zarour HM. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines. Cancer Res. 2014; 2014 Feb 15;74(4): 1045-55.
Fourcade J, Zarour HM. Strategies to reverse melanoma-induced T-cell dysfunction. Clin Dermatol. 2013 May-Jun;31(3):251-6. 2013.
Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM. CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1. Cancer Res. 2012 Feb 15;72(4):887-96. 2012.
Kudela P, Sun Z, Fourcade J, Janjic B, Kirkwood JM, Maillere B, Zarour HM. Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1. J Immunol. 2011 Jan 1;186(1):312-22. 2011.
Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010 Sep 27;207(10):2175-86. 2010.
Fourcade J, Sun Z, Kudela P, Janjic B, Kirkwood JM, El-Hafnawy T, Zarour HM. Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire. J Immunol. 2010 Jun 15;184(12):6709-18. 2010.
Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM, Zarour HM. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol. 2009 May 1;182(9):5240-9. 2009.
Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM, Zarour HM. Immunization with analogue peptide in combination with CpG and Montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother. 2008 Oct;31(8):781-91. 2008.
Kudela P, Janjic B, Fourcade J, Castelli F, Andrade P, Kirkwood JM, El-Hefnawy T, Amicosante M, Maillere B, Zarour HM. Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients. J Immunol. 2007; 2007 Dec 1;179(11): 7932-40.
Notable Achievements
AAI Trainee Abstract Award, 2014
Scholar-in-training Award AACR Annual Meeting, 2013
AACR Highly Rated Poster Presentation AACR 102nd Annual Meeting, 2011
AAI Trainee Abstract Award Experimental Biology, 2008